AU2001274886A1 - Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora - Google Patents

Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora

Info

Publication number
AU2001274886A1
AU2001274886A1 AU2001274886A AU7488601A AU2001274886A1 AU 2001274886 A1 AU2001274886 A1 AU 2001274886A1 AU 2001274886 A AU2001274886 A AU 2001274886A AU 7488601 A AU7488601 A AU 7488601A AU 2001274886 A1 AU2001274886 A1 AU 2001274886A1
Authority
AU
Australia
Prior art keywords
praziquantel
sarcocystis
compositions
neospora
isospora
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001274886A
Inventor
Thomas J. Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of AU2001274886A1 publication Critical patent/AU2001274886A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Disclosed herein are compositions and methods of treating therapeutically, or metaphylactically infected mammals susceptible to, or infected mammals suffering from parasitic neurologic or abortigenic diseases such as Sarcocystis, Neosporosis or Toxoplasmosis or Isosporosis that are treatable with a praziquantel compound by administering thereto a composition containing a pharmaceutically effective amount of praziquantel or derivative thereof, including metaphylactic and single high dose treatment regimens.
AU2001274886A 2000-05-23 2001-05-18 Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora Abandoned AU2001274886A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/576,791 2000-05-23
US09/576,791 US6429211B1 (en) 2000-05-23 2000-05-23 Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora
PCT/US2001/016440 WO2001089497A2 (en) 2000-05-23 2001-05-18 Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora

Publications (1)

Publication Number Publication Date
AU2001274886A1 true AU2001274886A1 (en) 2001-12-03

Family

ID=24306001

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001274886A Abandoned AU2001274886A1 (en) 2000-05-23 2001-05-18 Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora

Country Status (19)

Country Link
US (2) US6429211B1 (en)
EP (1) EP1296686B1 (en)
JP (1) JP4991076B2 (en)
KR (1) KR100821112B1 (en)
CN (1) CN1250222C (en)
AT (1) ATE310521T1 (en)
AU (1) AU2001274886A1 (en)
BR (1) BR0111014A (en)
CA (1) CA2409926C (en)
DE (1) DE60115237T2 (en)
DK (1) DK1296686T3 (en)
ES (1) ES2252242T3 (en)
HK (1) HK1059894A1 (en)
HU (1) HUP0302330A3 (en)
MX (1) MXPA02011453A (en)
NZ (1) NZ522687A (en)
PL (1) PL202041B1 (en)
WO (1) WO2001089497A2 (en)
ZA (1) ZA200208770B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061214A1 (en) * 2004-12-10 2006-06-15 Bayer Healthcare Ag Anthelmintic composition
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
US10137111B2 (en) 2016-08-11 2018-11-27 Adamis Pharmaceuticals Corporation Drug compositions comprising an anti-parasitic and proton pump inhibitor
US11564910B2 (en) 2017-12-08 2023-01-31 Adamis Pharmaceuticals Corporation Drug compositions
US20200138823A1 (en) * 2018-11-02 2020-05-07 Adamis Pharmaceuticals Corporation Drug compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2362539C2 (en) 1973-12-17 1986-05-07 Merck Patent Gmbh, 6100 Darmstadt 2-Acyl-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino [2,1-a] isoquinolines, processes for their preparation and pharmaceuticals containing these compounds
US4447414A (en) 1982-12-21 1984-05-08 Cutter Laboratories, Inc. Carnivore anthelmintics
DE3634755A1 (en) * 1986-10-11 1988-04-14 Bayer Ag DERMAL TREATMENT OF CAT WORM DISEASES WITH PRAZIQUANTEL
DE3805660A1 (en) 1988-02-24 1989-09-07 Bayer Ag SUBSTITUTED 1,2,4-TRIAZINDIONES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
DE3826058A1 (en) 1988-07-30 1990-02-08 Bayer Ag AGAINST FISH PARASITES
US4933341A (en) 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
US5196562A (en) 1988-10-08 1993-03-23 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
EP0377903A3 (en) 1989-01-09 1991-07-17 Bayer Ag Substituted hexahydro-1,2,4-triazine diones, processes for their preparation, intermediates and their use
CN1044905A (en) 1989-02-16 1990-08-29 赫彻斯特股份公司 Fish and entomophagous parasite worm antagonist
DE4030042A1 (en) 1990-05-17 1991-11-21 Bayer Ag USE OF SUBSTITUTED 1,2,4-TRIAZINDIONES
DE4120138A1 (en) 1991-06-19 1992-12-24 Bayer Ag SUBSTITUTED HEXAHYDRO-1,2,4-TRIAZINDIONES, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS THEREOF AND THEIR USE
AUPM969994A0 (en) 1994-11-28 1994-12-22 Virbac S.A. Equine anthelmintic formulations
US5663155A (en) 1994-11-30 1997-09-02 The University Hospital Compositions for the treatment of parasitic infections
JPH0987196A (en) * 1995-09-25 1997-03-31 Masatoshi Nakano Parasite repellent
US6051604A (en) * 1995-12-07 2000-04-18 The Proctor & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
AU5529600A (en) * 1999-06-18 2001-01-09 Bayer Aktiengesellschaft Anthelmintic compositions

Also Published As

Publication number Publication date
NZ522687A (en) 2004-07-30
EP1296686B1 (en) 2005-11-23
PL202041B1 (en) 2009-05-29
DE60115237T2 (en) 2006-06-29
DK1296686T3 (en) 2006-04-03
CN1452489A (en) 2003-10-29
PL360503A1 (en) 2004-09-06
HK1059894A1 (en) 2004-07-23
DE60115237D1 (en) 2005-12-29
ES2252242T3 (en) 2006-05-16
US20020143018A1 (en) 2002-10-03
MXPA02011453A (en) 2003-05-23
ATE310521T1 (en) 2005-12-15
WO2001089497A3 (en) 2002-11-28
BR0111014A (en) 2003-04-08
HUP0302330A3 (en) 2012-02-28
KR20020097257A (en) 2002-12-31
CA2409926A1 (en) 2001-11-29
US6429211B1 (en) 2002-08-06
ZA200208770B (en) 2003-10-30
CA2409926C (en) 2009-11-03
JP4991076B2 (en) 2012-08-01
HUP0302330A2 (en) 2003-11-28
WO2001089497A2 (en) 2001-11-29
JP2003534275A (en) 2003-11-18
EP1296686A2 (en) 2003-04-02
CN1250222C (en) 2006-04-12
KR100821112B1 (en) 2008-04-11

Similar Documents

Publication Publication Date Title
AU3664401A (en) Platelet adp receptor inhibitors
AU2002360592A1 (en) Inhibitors of hepatitis c virus
EA200701869A1 (en) PEPTIDOMYMETIC PROTEASE INHIBITORS
LU91254I2 (en) Daptomycin and its pharmaceutically acceptable derivatives (cubicinr)
EA200001085A1 (en) 5-AMINOINDENO [1, 2-C] PYRAZOL-4-ONE AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS
HK1043315A1 (en) Triazineone compounds for treating diseases due tosarcosystis, neospora and toxoplasma.
EA200200995A1 (en) APPLICATION OF AZALIDE ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF BACTERIAL OR PROTOSOIC INFECTIONS IN MAMMALS
BR0004538A (en) Effective combination for the treatment of impotence
AU2001274886A1 (en) Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer
CA2355825A1 (en) Triazineone compounds for treating diseases due to sarcocystis, neospora and toxoplasma
AU2003274800A1 (en) Anticancer or antiviral composition
EA200500398A1 (en) Β-lactamase inhibitor treatment
DE50109320D1 (en) USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE COMPOUNDS FOR THE THERAPY OF HARNINE INCONTINENCE
MXPA05012895A (en) Beta-lactamase inhibitor prodrug.
WO2004000864A3 (en) 11-c-substituted ketolides
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
LV12459A (en) Compound and pharmaceutical compositions for the treatment of related diseases by triptase activity